User login
Extended-release versions of oxybutynin and tolterodine are similarly effective and tolerable in the treatment of women with overactive bladder. No differences are seen in reduction of weekly episodes of urge incontinence and total incontinence after 3 months of treatment. Extended-release oxybutynin is more effective than extended-release tolterodine in promoting total dryness (no episodes of incontinence) after 12 weeks of treatment. Dry mouth is more common with oxybutynin; however, other side effects are similar.
Extended-release versions of oxybutynin and tolterodine are similarly effective and tolerable in the treatment of women with overactive bladder. No differences are seen in reduction of weekly episodes of urge incontinence and total incontinence after 3 months of treatment. Extended-release oxybutynin is more effective than extended-release tolterodine in promoting total dryness (no episodes of incontinence) after 12 weeks of treatment. Dry mouth is more common with oxybutynin; however, other side effects are similar.
Extended-release versions of oxybutynin and tolterodine are similarly effective and tolerable in the treatment of women with overactive bladder. No differences are seen in reduction of weekly episodes of urge incontinence and total incontinence after 3 months of treatment. Extended-release oxybutynin is more effective than extended-release tolterodine in promoting total dryness (no episodes of incontinence) after 12 weeks of treatment. Dry mouth is more common with oxybutynin; however, other side effects are similar.